??5-alpha reductase inhibitors and prostate cancer prevention: where do we turn now?
With the lifetime risk of being diagnosed with prostate cancer so great, an effective chemopreventive agent could have a profound impact on the lives of men. Despite decades of searching for such an agent, physicians still do not have an approved drug to offer their patients.Here, we outline current strategies for preventing prostate cancer in general, with a focus on the 5-alpha-reductase inhibitors (5-ARI) finasteride and dutasteride. We discuss the two landmark randomized controlled trials for finasteride and dutasteride, highlighting the controversies stemming from the results and address the issue of 5-ARI usage, including reasons why providers may be hesitant to use these agents for chemoprevention.
We further discuss the recent United States Food and Drug Administration ruling against the proposed new indication for dutasteride and the change to the labeling of finasteride, both of which were intended to permit physicians to use the drugs for chemoprevention. Finally, we discuss future directions for 5-ARI research.
Author: Robert HamiltonStephen Freedland
Credits/Source: BMC Medicine 2011, 9:105
Published on: 2011-09-15
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
albuquerque college football scores dish tv dish tv hamilton apollo 18 trailer keanu reeves
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন